ClinicalTrials.gg
CompletedNCT00231816Updated Sep 21, 2015Results posted

A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011)

A Phase 3 interventional study of ZOSTAVAX™ (concomitant) and Comparator: Influenza Vaccine in Herpes Zoster, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-09-21.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
763
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing Chickenpox Vaccine in Herpes Zoster — none open to participants now, none under way, none of them phase 3. Chickenpox Vaccine · Herpes Zoster.

Enrollment
4th of 29
763 · median 160
Started
2005
the only one that year
Phase 3
9 of 29
none open now
Registered
2nd of 29
by date
Lead sponsor
15 of 29
Merck Sharp & Dohme LLC

Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, this one is the 4th largest by enrollment, is the only one that started in 2005, is one of 9 in phase 3, and was the 2nd registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

None of the 29 studies testing Chickenpox Vaccine in Herpes Zoster is open now. The open studies under Herpes Zoster, anywhere →

About Chickenpox Vaccine

Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies testing Chickenpox Vaccine in Herpes Zoster as a file.
02

Study summary

The purpose of this study is to determine whether the investigational zoster vaccine has a comparable immune response (the body's ability to protect against disease) and safety profile when given concomitantly with another vaccine.

03

Conditions studied

  • Herpes Zoster

Browse trials for

Keywords

  • Prevention of Herpes Zoster
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults 50 years of age or older

Exclusion criteria

Exclusion Criteria:

  • Prior history of Herpes Zoster (shingles)
  • Prior receipt of varicella or zoster vaccine
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
763 participants (actual)

Study arms

  • Experimental
    Concomitant

    Zostavax concomitantly with influenza vaccine on Day 1, placebo at week 4

    Biological: ZOSTAVAX™ (concomitant) · Biological: Comparator: Influenza Vaccine

  • Experimental
    Nonconcomitant

    Influenza vaccine and Zostavax placebo on Day 1, Zostavax at week 4

    Biological: Comparator: Influenza Vaccine · Biological: ZOSTAVAX™ (Nonconcomitant)

Interventions

  • a single administration of 0.65 mL subcutaneous injection of zoster vaccine live on Day 1 and placebo at Week 4

    Also known as: V211

  • BiologicalComparator: Influenza Vaccine

    a single administration of 0.5 mL intramuscular injection of influenza vaccine (inactivated) at Day 1

    Also known as: Fluzone, Vaxigrip

  • Placebo injection on Day 1 and a single administration of 0.65 mL subcutaneous injection of zoster vaccine live at Week 4

06

What researchers measure

Primary outcomes

  1. Varicella-zoster Virus (VZV) Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Antibody Responses

    The Geometric mean titer (GMT) of the VZV glycoprotein enzyme-linked immunosorbent assay (gpELISA) antibody responses at Week 4 postvaccination in participants who received ZOSTAVAX™ concomitantly with influenza vaccine was compared to that in subjects who received influenza vaccine and ZOSTAVAX™ nonconcomitantly.

    Time frame: 4 weeks

Other outcomes

  1. Geometric Mean Fold Rise (GMFR) in VZV gpELISA Antibody Titers From Prevaccination to 4 Weeks Postvaccination

    GMFR of the VZV gpELISA antibody titers from prevaccination to 4 weeks postvaccination when ZOSTAVAX™ is administered concomitantly with influenza vaccine

    Time frame: prevaccination to 4 weeks postvaccination

  2. Geometric Mean Titers (GMTs) of H1N1 Strain Antibody Responses at 4 Weeks Postvaccination

    GMT of the H1N1 strain antibody responses at 4 weeks postvaccination in participants who receive ZOSTAVAX™ concomitantly with influenza vaccine and those who receive ZOSTAVAX™ and influenza vaccine nonconcomitantly

    Time frame: 4 weeks postvaccination

  3. GMTs of H3N2 Strain Antibody Responses at 4 Weeks Postvaccination

    GMT of the H3N2 strain antibody responses at 4 weeks postvaccination in participants who receive ZOSTAVAX™ concomitantly with influenza vaccine and those who receive ZOSTAVAX™ and influenza vaccine nonconcomitantly

    Time frame: 4 weeks postvaccination

  4. GMTs of B Strain Antibody Responses at 4 Weeks Postvaccination

    GMT of the B strain antibody responses at 4 weeks postvaccination in participants who receive ZOSTAVAX™ concomitantly with influenza vaccine and those who receive ZOSTAVAX™ and influenza vaccine nonconcomitantly

    Time frame: 4 weeks postvaccination

07

Results

Posted Dec 15, 2010

Participant flow

Participants were recruited at 13 sites in the United States and 7 sites in Europe. First Patient In (FPI): 23-SEP-2005; Last Patient Last Visit (LPLV): 08-MAR-2006

Participant flow — Overall Study
MilestoneConcomitant GroupNonconcomitant Group
Started382381
Vaccinated at visit 1382380
Vaccinated at visit 2369371
Completed366369
Not completed1612
Withdrew: Adverse event10
Withdrew: Lost to follow-up85
Withdrew: Protocol violation23
Withdrew: Withdrawal by subject33
Withdrew: Other21

Outcome measures

PrimaryVaricella-zoster Virus (VZV) Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Antibody Responses

The Geometric mean titer (GMT) of the VZV glycoprotein enzyme-linked immunosorbent assay (gpELISA) antibody responses at Week 4 postvaccination in participants who received ZOSTAVAX™ concomitantly with influenza vaccine was compared to that in subjects who received influenza vaccine and ZOSTAVAX™ nonconcomitantly.

Time frame:
4 weeks
Reported as:
Geometric mean · gpELISA units/mL
Varicella-zoster Virus (VZV) Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Antibody Responses
gpELISA units/mLConcomitant GroupNonconcomitant Group
Varicella-zoster Virus (VZV) Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Antibody Responses553.5 (499.0 to 613.9)588.7 (531.9 to 651.5)
Other pre-specifiedGeometric Mean Fold Rise (GMFR) in VZV gpELISA Antibody Titers From Prevaccination to 4 Weeks Postvaccination

GMFR of the VZV gpELISA antibody titers from prevaccination to 4 weeks postvaccination when ZOSTAVAX™ is administered concomitantly with influenza vaccine

Time frame:
prevaccination to 4 weeks postvaccination
Reported as:
Geometric mean · ratio
Geometric Mean Fold Rise (GMFR) in VZV gpELISA Antibody Titers From Prevaccination to 4 Weeks Postvaccination
ratioConcomitant Group
Geometric Mean Fold Rise (GMFR) in VZV gpELISA Antibody Titers From Prevaccination to 4 Weeks Postvaccination2.1 (2.0 to 2.3)
Other pre-specifiedGeometric Mean Titers (GMTs) of H1N1 Strain Antibody Responses at 4 Weeks Postvaccination

GMT of the H1N1 strain antibody responses at 4 weeks postvaccination in participants who receive ZOSTAVAX™ concomitantly with influenza vaccine and those who receive ZOSTAVAX™ and influenza vaccine nonconcomitantly

Time frame:
4 weeks postvaccination
Reported as:
Geometric mean · titers
Geometric Mean Titers (GMTs) of H1N1 Strain Antibody Responses at 4 Weeks Postvaccination
titersConcomitant GroupNonconcomitant Group
Geometric Mean Titers (GMTs) of H1N1 Strain Antibody Responses at 4 Weeks Postvaccination122.9 (107.8 to 140.0)134.2 (118.3 to 152.2)
Other pre-specifiedGMTs of H3N2 Strain Antibody Responses at 4 Weeks Postvaccination

GMT of the H3N2 strain antibody responses at 4 weeks postvaccination in participants who receive ZOSTAVAX™ concomitantly with influenza vaccine and those who receive ZOSTAVAX™ and influenza vaccine nonconcomitantly

Time frame:
4 weeks postvaccination
Reported as:
Geometric mean · titers
GMTs of H3N2 Strain Antibody Responses at 4 Weeks Postvaccination
titersConcomitant GroupNonconcomitant Group
GMTs of H3N2 Strain Antibody Responses at 4 Weeks Postvaccination162.7 (140.4 to 188.4)150.5 (129.8 to 174.5)
Other pre-specifiedGMTs of B Strain Antibody Responses at 4 Weeks Postvaccination

GMT of the B strain antibody responses at 4 weeks postvaccination in participants who receive ZOSTAVAX™ concomitantly with influenza vaccine and those who receive ZOSTAVAX™ and influenza vaccine nonconcomitantly

Time frame:
4 weeks postvaccination
Reported as:
Geometric mean · titers
GMTs of B Strain Antibody Responses at 4 Weeks Postvaccination
titersConcomitant GroupNonconcomitant Group
GMTs of B Strain Antibody Responses at 4 Weeks Postvaccination119.8 (104.8 to 137.1)136.5 (120.5 to 154.7)

Adverse events

Collected over Day 1-28 following each vaccination. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Concomitant Group—6/378 (1.6%)199/378 (52.6%)
Nonconcomitant Group—5/376 (1.3%)181/376 (48.1%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventConcomitant GroupNonconcomitant Group
Cardiac failure congestiveCardiac disorders3/3780/376
AnaemiaBlood and lymphatic system disorders0/3781/376
Angina unstableCardiac disorders0/3781/376
AppendicitisInfections and infestations0/3781/376
Upper limb fractureInjury, poisoning and procedural complications0/3781/376
Back painMusculoskeletal and connective tissue disorders0/3781/376
Aortic valve stenosisCardiac disorders1/3780/376
ArrhythmiaCardiac disorders1/3780/376
Myocardial infarctionCardiac disorders1/3780/376
PneumoniaInfections and infestations1/3780/376
Most frequent other events
Most frequent other events
EventConcomitant GroupNonconcomitant Group
Injection Site Erythema (ZOSTAVAX™ injection site)General disorders125/378101/376
Injection Site Pain (ZOSTAVAX™ injection site)General disorders114/378107/376
Injection Site Swelling (ZOSTAVAX™ injection site)General disorders70/37894/376
Injection Site Pain (Influenza vaccine injection site)General disorders90/37886/376
Injection Site Erythema (Influenza vaccine injection site)General disorders46/37829/376
Injection Site Swelling (Influenza vaccine injection site)General disorders41/37831/376
Injection Site Pain (Placebo injection site)General disorders16/37823/376
Injection Site Erythema (Placebo injection site)General disorders11/37819/376
Upper respiratory tract infectionInfections and infestations19/37817/376

Baseline characteristics

Age, Continuous
Age, Continuous(years)Concomitant GroupNonconcomitant GroupTotal
Mean63.4 ± 7.9963.6 ± 8.2463.5 ± 8.11
Sex: Female, Male
Sex: Female, Male(Participants)Concomitant GroupNonconcomitant GroupTotal
Female215212427
Male167168335
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Concomitant GroupNonconcomitant GroupTotal
African101
Asian549
Black106100206
Hispanic American111122
Indian011
Multiracial022
Native American112
White258261519
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Kerzner B, Murray AV, Cheng E, Ifle R, Harvey PR, Tomlinson M, Barben JL, Rarrick K, Stek JE, Chung MO, Schodel FP, Wang WW, Xu J, Chan IS, Silber JL, Schlienger K. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older. J Am Geriatr Soc. 2007 Oct;55(10):1499-507. doi: 10.1111/j.1532-5415.2007.01397.x. PubMed 17908055 ↗
  • Sutradhar SC, Wang WW, Schlienger K, Stek JE, Xu J, Chan IS, Silber JL. Comparison of the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and in adults 60 years old or older. Clin Vaccine Immunol. 2009 May;16(5):646-52. doi: 10.1128/CVI.00407-08. Epub 2009 Mar 4. PubMed 19261769 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005, a primary completion of Mar 2006 and a completion of Mar 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2010, 4 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2005
First posted
Oct 4, 2005
Start
Sep 2005
Primary completionActual
Mar 2006
CompletionActual
Mar 2006
Results first posted
Dec 15, 2010
Last update
Sep 21, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00231816
Responsible party
Sponsor
First posted
Oct 4, 2005
Start date
Sep 2005
Primary completion
Mar 2006
Completion
Mar 2006
Results posted
Dec 15, 2010
Last update
Sep 21, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chickenpox Vaccine

Start the discussion